Skip to main content
. 2023 Feb 24;23:115. doi: 10.1186/s12879-023-08026-0

Table 1.

Demographics and Clinical Characteristics at COVID-19 Admission of the Analytical Cohort, Northwestern Medical Group, March 2020-September 2022

Non-antecedent statin user (n = 11,112) Antecedent statin user (n = 4,412)
Baseline variables
 Age, mean (SD) 65.56 (14.53) 72.09 (12.62)
 Male sex, n (%) 5635 (50.7) 2386 (54.1)
 Race, n (%)
  Asian 338 (3.1) 127 (2.9)
  Black 1468 (13.5) 606 (13.9)
  Multiracial1 198 (1.8) 53 (1.2)
  White 7767 (71.3) 3329 (76.3)
  Other2 1117 (10.3) 248 (5.7)
  Hispanic/Latino/x ethnicity, n (%) 1927 (17.3) 367 (8.3)
 County, n (%)
  Cook 3033 (28.4) 1227 (28.2)
  DeKalb 760 (7.1) 419 (9.6)
  DuPage 1835 (17.2) 722 (16.6)
  Kane 1044 (9.8) 508 (11.7)
  Lake 1622 (15.2) 489 (11.2)
  McHenry 1629 (15.3) 744 (17.1)
  Others in Illinois3 374 (3.5) 147 (3.4)
  Non-Illinois Areas 375 (3.5) 93 (2.1)
 Site
  1 2199 (19.8) 848 (19.2)
  2 931 (8.4) 487 (11.0)
  3 1153 (10.4) 395 (9.0)
  4 718 (6.5) 371 (8.4)
  5 1488 (13.4) 435 (9.9)
  6 1221 (11.0) 605 (13.7)
  7 3212 (28.9) 1211 (27.4)
  8, 9 or 10 190 (1.7) 60 (1.4)
BMI ≥ 25, n (%) 7336 (73.5) 2908 (73.2)
Ever smoked, n (%) 2311 (20.8) 662 (15.0)
 Vaccination status on admission, n (%)
  None 8656 (77.9) 2353 (53.3)
  Incomplete 1197 (10.8) 960 (21.8)
  Full 222 (2.0) 162 (3.7)
  Boosted 1037 (9.3) 937 (21.2)
 Quarter and Year of Admission, n (%)
  2020 Quarter 1 249 (2.2) 10 (0.2)
  2020 Quarter 2 1456 (13.1) 143 (3.2)
  2020 Quarter 3 512 (4.6) 107 (2.4)
  2020 Quarter 4 2384 (21.5) 726 (16.5)
  2021 Quarter 1 978 (8.8) 411 (9.3)
  2021 Quarter 2 623 (5.6) 194 (4.4)
  2021 Quarter 3 607 (5.5) 233 (5.3)
  2021 Quarter 4 1224 (11.0) 547 (12.4)
  2022 Quarter 1 1335 (12.0) 745 (16.9)
  2022 Quarter 2 679 (6.1) 503 (11.4)
  2022 Quarter 3 835 (7.5) 636 (14.4)
  2022 Quarter 4 230 (2.1) 157 (3.6)
 Initial Clinical Presentation, mean (SD)
  Heart Rate (per minute), 90.30 (19.09) 86.82 (19.74)
  Respiratory rate (per minute) 21.09 (5.76) 20.66 (5.18)
  Systolic blood pressure (mmHg) 136.33 (25.19) 137.46 (26.81)
  Diastolic blood pressure (mmHg) 75.10 (14.38) 72.96 (14.80)
  Oxygen Saturation (%) 94.54 (6.22) 95.08 (4.81)
 Comorbidities at baseline, n (%)
  Asthma 1396 (12.6) 825 (18.7)
  Cancer 3068 (27.6) 1852 (42.0)
  Cardiovascular disease 5152 (46.4) 3537 (80.2)
  Chronic liver disease 449 (4.0) 243 (5.5)
  COPD 1195 (10.8) 1005 (22.8)
  Cardiovascular disease 5152 (46.4) 3537 (80.2)
  Diabetes mellitus 3356 (30.2) 2397 (54.3)
  HIV 260 (2.3) 196 (4.4)
  Hypertension 6902 (62.1) 4013 (91.0)
  Immune disorder 1071 (9.6) 708 (16.0)
  Renal disease 3227 (29.0) 2413 (54.7)
 Treatment during admission, n (%)
  Bamlanivumab 10 (0.1) 12 (0.3)
  Dexamethasone 5368 (48.3) 2120 (48.1)
  Remdesivir 4438 (39.9) 2006 (45.5)
  Sarilumab 15 (0.1) 1 (0.0)
  Tocilizumbab 512 (4.6) 96 (2.2)
  Steroids 6221 (56.0) 2532 (57.4)
  Immune modulator4 401 (3.6) 285 (6.5)
 Outcomes
  Composite inpatient outcome, n (%) 2140 (19.3) 653 (14.8)
  ICU admission, n (%) 2034 (18.3) 614 (13.9)
  Intubation, n (%) 919 (8.3) 226 (5.1)
  Inpatient death, n (%) 583 (5.2) 196 (4.4)
  Time to composite outcome, median [IQR] 0.31 [0.14, 2.69] 0.41 [0.18, 3.54]
  Length of Stay, median [IQR] 4.88 [2.80, 8.84] 4.51 [2.81, 7.89]

BMI: body mass index, COPD: chronic obstructive pulmonary disease

1Multiracial individuals are people who report more than two categories (e.g., Asian and Black)

2Others include American Indian, Alaska Native, Native Hawaiian, Pacific-Islander, Guamanian, and Chamorro or chose other or none of the above

3Other Illinois counties include all other counties not listed in the table

4See methods supplement for complete list of immune-modulator drugs. Variables with missing data: Body mass index (10%), county (3%), race (2%), insurance (0.1%), Systolic blood pressure (0.05%), Diastolic blood pressure (0.05%), Oxygen saturation (0.03%)